Religare Enterprises is currently trading at Rs. 227.05, up by 8.70 points or 3.98% from its previous closing of Rs. 218.35 on the BSE.
The scrip opened at Rs. 228.95 and has touched a high and low of Rs. 230.00 and Rs. 228.30 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 294.90 on 08-Apr-2016 and a 52 week low of Rs. 209.00 on 10-Mar-2017.
Last one week high and low of the scrip stood at Rs. 234.00 and Rs. 216.00 respectively. The current market cap of the company is Rs. 4,070.00 crore.
The promoters holding in the company stood at 50.93%, while Institutions and Non-Institutions held 20.57% and 28.51% respectively.
Religare Enterprises (REL) has entered into a definitive agreement with a consortium of investors led by True North (formerly India Value Fund) to buy out its entire stake in Religare Health Insurance Company (RHI). The consortium includes domestic investors such as Gaurav Dalmia and Faering Capital. JP Morgan acted as the exclusive financial advisor to Religare Enterprises on this transaction.
This transaction values RHI at Rs 1,300 crore and REL currently has 80% shareholding on a fully diluted basis in RHI. The transaction marks the single largest investment in a standalone health insurance company in India. The transaction is subject to necessary regulatory approvals.
Religare Enterprises is one of India’s leading diversified financial services groups. It offers an integrated suite of financial services including asset management, life and health insurance, lending, broking, investment banking, and wealth management.
